References
- Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM. Leptomeningeal metastases in the MRI era. Neurology. 2010;74:1449–54.
- Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, et al.. Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol. 2010;21:2183–7.
- Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, et al.. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer. 1996;77:1315–23.
- Rudnicka H, Niwińska A, Murawska M. Breast cancer leptomeningeal metastasis−the role of multimodality treatment. J Neurooncol. 2007;84:57–62.
- Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38:51–7.
- Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol. 2010;11:871–9.
- Chamberlain MC. Neoplastic meningitis. J Clin Oncol. 2005;23:3605–13.
- Chamberlain MC, Kormanik PR. Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol. 1997;35:55–64.
- Chamberlain MC. Leptomeningeal metastasis. Curr Opin Oncol. 2010;22:627–35.
- De Azevedo CR, Cruz MR, Chinen LT, Peres SV, Peterlevitz MA, De Azevedo Pereira AE, et al.. Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neurooncol. 2011;104:565–72.
- Boogerd W, Hart AA, van der Sande JJ, Engelsman E. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer. 1991;67:1685–95.
- Chamberlain MC, Johnston SK. Neoplastic meningitis: survival as a function of cerebrospinal fluid cytology. Cancer. 2009;115:1941–6.
- Bidard FC, Lossignol D, Larsimont D, Piccart M, Awada A. Validation of the Institut Curie simplified prognostic score for breast cancer meningeal carcinomatosis. Ann Oncol. 2011;22:480–2.
- Waki F, Ando M, Takashima A, Yonemori K, Nokihara H, Miyake M, et al.. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol. 2009;93:205–12.
- Jayson GC, Howell A, Harris M, Morgenstern G, Chang J, Ryder WD. Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer. 1994,74:3135–41.
- Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999;25:103–19.
- Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, et al.. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007;110:2640–7.
- Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol. 2010;136:1729–35.
- Yap HY, Yap BS, Rasmussen S, Levens ME, Hortobagyi GN, Blumenschein GR. Treatment for meningeal carcinomatosis in breast cancer. Cancer. 1982;50:219–22.
- Perissinotti AJ, Reeves DJ. Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. Ann Pharmacother. 2010;44:1633–40.
- Yu H, Mitsumori M, Nagata Y, Katakura Y, Kokubo M, Oya N, et al.. Meningeal carcinomatosis in patients with breast cancer: report of 8 patients. Breast Cancer. 2001;8:74–8.
- Kosmas C, Malamos NA, Tsavaris NB, Stamataki M, Stefanou S, Gregoriou A, et al.. Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer. J Neurooncol. 2002;56:265–73.